Morgan Stanley’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-594,393
| Closed | -$12.9M | – | 6742 |
|
|
2017
Q2 | $12.9M | Sell |
594,393
-137,245
| -19% | -$2.49M | ﹤0.01% | 1929 |
|
|
2017
Q1 | $10.3M | Buy |
731,638
+115,040
| +19% | +$1.88M | ﹤0.01% | 2173 |
|
|
2016
Q4 | $11.6M | Buy |
616,598
+32,627
| +6% | +$555K | ﹤0.01% | 2094 |
|
|
2016
Q3 | $9.64M | Sell |
583,971
-147,797
| -20% | -$2.19M | ﹤0.01% | 2043 |
|
|
2016
Q2 | $9.84M | Buy |
731,768
+7,696
| +1% | +$112K | ﹤0.01% | 1993 |
|
|
2016
Q1 | $11.1M | Buy |
724,072
+256,293
| +55% | +$4.02M | ﹤0.01% | 1783 |
|
|
2015
Q4 | $9.29M | Sell |
467,779
-284,613
| -38% | -$5.41M | ﹤0.01% | 2053 |
|
|
2015
Q3 | $13.1M | Buy |
752,392
+236,998
| +46% | +$4.83M | ﹤0.01% | 1718 |
|
|
2015
Q2 | $10.4M | Sell |
515,394
-85,610
| -14% | -$1.65M | ﹤0.01% | 2070 |
|
|
2015
Q1 | $10.6M | Sell |
601,004
-23,438
| -4% | -$399K | ﹤0.01% | 2000 |
|
|
2014
Q4 | $10.2M | Sell |
624,442
-1,049,132
| -63% | -$19.3M | ﹤0.01% | 2055 |
|
|
2014
Q3 | $36.9M | Buy |
1,673,574
+942,089
| +129% | +$19.3M | 0.01% | 984 |
|
|
2014
Q2 | $14.7M | Buy |
731,485
+147,358
| +25% | +$2.5M | 0.01% | 1688 |
|
|
2014
Q1 | $10.9M | Sell |
584,127
-45,373
| -7% | -$625K | ﹤0.01% | 1898 |
|
|
2013
Q4 | $6.34M | Buy |
629,500
+205,800
| +49% | +$2.49M | ﹤0.01% | 2353 |
|
|
2013
Q3 | $5.46M | Sell |
423,700
-248,585
| -37% | -$3.06M | ﹤0.01% | 2341 |
|
|
2013
Q2 | $7.98M | Buy |
+672,285
| New | +$7.28M | ﹤0.01% | 1882 |
|
Other funds holding AMRI
Morgan Stanley's AMRI Position: Q3 2017 in Review
Morgan Stanley sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 594,393 shares — an estimated $12.9M sold.
Morgan Stanley first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $36.9M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Morgan Stanley reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Morgan Stanley sold 594,393 Albany Molecular Research Inc shares in Q3 2017, an estimated $12.9M.
- Morgan Stanley first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Morgan Stanley's Albany Molecular Research Inc position peaked at $36.9M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Morgan Stanley's 13F filing for Q3 2017, filed 14 Nov 2017.